M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Cytoxan
Drug: Nipent
Drug: Rituxan

First Posted Date: 2007-07-04

Last Posted Date: 2023-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00496873

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Azacitidine
Drug: Valproic Acid

First Posted Date: 2007-07-04

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00496444

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Proton Beam Therapy for Chordoma Patients

Phase 2

Active, not recruiting

Conditions: Chordoma

Interventions: Radiation: Proton Beam Therapy
Radiation: Photon Beam Therapy

First Posted Date: 2007-07-04

Last Posted Date: 2024-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00496119

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Proton Beam Therapy for Chondrosarcoma

Phase 2

Active, not recruiting

Conditions: Chondrosarcoma

Interventions: Procedure: Proton Beam Therapy

First Posted Date: 2007-07-04

Last Posted Date: 2025-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00496522

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Not Applicable

Completed

Conditions: Ductal Carcinoma In Situ

Interventions: Drug: Herceptin (Trastuzumab)

First Posted Date: 2007-07-04

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00496808

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Capecitabine
Drug: Gemcitabine
Drug: Bevacizumab

First Posted Date: 2007-07-04

Last Posted Date: 2017-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00496587

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

Completed

Conditions: Endometrial Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-03

Last Posted Date: 2014-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 147

Registration Number: NCT00495235

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Ben Taub Hospital, Houston, Texas, United States
🇺🇸
Gynecologic Oncology of Houston, Houston, Texas, United States

and more 5 locations

Prospective Measurement of Post-Treatment Lymphedema

Completed

Conditions: Melanoma

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-03

Last Posted Date: 2016-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 350

Registration Number: NCT00495950

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Sorafenib
Drug: Sunitinib
Drug: Erlotinib
Drug: Lapatinib
Drug: Dasatinib
Drug: Lenalidomide
Drug: Valproic Acid

First Posted Date: 2007-07-03

Last Posted Date: 2012-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 204

Registration Number: NCT00495872

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Radiation: Proton Radiotherapy

First Posted Date: 2007-07-02

Last Posted Date: 2019-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00495040

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy